Format

Send to

Choose Destination
Support Care Cancer. 2019 Oct;27(10):3729-3737. doi: 10.1007/s00520-019-04987-8. Epub 2019 Jul 30.

Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.

Author information

1
National University of Singapore, Singapore, Singapore.
2
National Cancer Centre Singapore, Singapore, Singapore.
3
University of Michigan, Ann Arbor, USA.
4
University Hospital Ntra. Sra. de Candelaria, Santa Cruz de Tenerife, Spain.
5
The Ohio State University Comprehensive Cancer Center, Columbus, USA.
6
University of Connecticut, Storrs, USA.
7
East Carolina University, Greenville, USA.
8
Mayo Clinic Rochester, Florida, USA.
9
University of Connecticut Health Center, Storrs, USA.
10
MD Anderson Cancer Center, Houston, USA.
11
University of Colorado, Colorado, USA.
12
VA Eastern Colorado Health Care Systems, Aurora, MS, USA.
13
Western University of Health Sciences, Pomona, USA.
14
University of California San Francisco, San Francisco, USA.
15
Zuckerberg San Francisco General Hospital, San Francisco, USA.
16
Northwell Cancer Institute, New Hyde Park, USA.
17
Zucker School of Medicine at Hofstra, 500 Hofstra Blvd, Hempstead, USA.
18
Marie Curie Hospital, , London, UK.
19
University of Trieste, Trieste, Italy.
20
Helen Diller Comprehensive Cancer Centre, San Francisco, USA.
21
University of Toronto, Toronto, Canada.
22
Preston Robert Tisch Brain Tumor Centre, Durham, USA.
23
The Ohio State University Comprehensive Cancer Center, Columbus, USA. maryam.lustberg@osumc.edu.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.

KEYWORDS:

CIPN; Chemotherapy-induced peripheral neuropathy; Neuropathy

PMID:
31363906
PMCID:
PMC6728179
[Available on 2020-10-01]
DOI:
10.1007/s00520-019-04987-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center